A consensus panel of genes derived from EGFR-associated progression pathways (e.g. fDEGs, invGRN, EGFR-related EMT) represents a promising predictive marker but cannot be assessed using sub-genomic panel sequencing, the current standard in routine molecular diagnostics for cancer patients. This evidence concerns the gene EGFR and cancer.